Rovi/€ROVI
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Rovi
Laboratorios Farmaceuticos ROVI SA, ticker ROVI, is a Spain-based pharmaceutical company primarily engaged in developing, manufacturing, and commercializing pharmaceutical products. The company's activities span both domestic and international markets, focusing on a range of medical and drug treatments. Founded in 1946, ROVI continues to expand its reach and influence in the healthcare and pharmaceutical sectors.
Ticker
€ROVI
Sector
Primary listing
BME
Industry
Pharmaceuticals
Headquarters
Employees
2,188
Website
Rovi Metrics
BasicAdvanced
€2.8B
21.36
€2.59
0.45
€0.76
1.37%
Price and volume
Market cap
€2.8B
Beta
0.45
52-week high
€89.45
52-week low
€45.52
Average daily volume
89K
Dividend rate
€0.76
Financial strength
Current ratio
2.768
Quick ratio
0.976
Long term debt to equity
17.636
Total debt to equity
22.498
Dividend payout ratio (TTM)
42.68%
Interest coverage (TTM)
56.91%
Profitability
EBITDA (TTM)
194.512
Gross margin (TTM)
62.40%
Net profit margin (TTM)
17.66%
Operating margin (TTM)
23.05%
Effective tax rate (TTM)
22.75%
Revenue per employee (TTM)
€340,000
Management effectiveness
Return on assets (TTM)
12.50%
Return on equity (TTM)
25.01%
Valuation
Price to earnings (TTM)
21.364
Price to revenue (TTM)
3.773
Price to book
5.01
Price to tangible book (TTM)
5.29
Price to free cash flow (TTM)
39.157
Free cash flow yield (TTM)
2.55%
Free cash flow per share (TTM)
1.412
Dividend yield (TTM)
1.37%
Forward dividend yield
1.37%
Growth
Revenue change (TTM)
-3.73%
Earnings per share change (TTM)
-8.80%
3-year revenue growth (CAGR)
0.45%
10-year revenue growth (CAGR)
11.91%
3-year earnings per share growth (CAGR)
-8.23%
10-year earnings per share growth (CAGR)
18.91%
3-year dividend per share growth (CAGR)
-0.72%
10-year dividend per share growth (CAGR)
18.66%
What the Analysts think about Rovi
Analyst ratings (Buy, Hold, Sell) for Rovi stock.
Bulls say / Bears say
Rovi's ambitious 2030 outlook projects operating revenue to reach between €1,146 million and €1,375 million, driven by significant growth in its Contract Development and Manufacturing Organization (CDMO) business, which is expected to contribute approximately €700 million by 2030. (Investing.com)
The company's specialty pharmaceutical segment showed strong performance in Q1 2025, with Okedi® (Risperidone ISM®) sales surging 133% year-over-year to €12.6 million, indicating successful commercialization and market acceptance. (Investing.com)
Rovi received a €36.3 million grant for research into prolonged-release investigational drugs and new aseptic filling technologies, which is expected to cover about 40% of the company's R&D investment needs over the next two fiscal years, supporting its innovation pipeline. (TradingView News)
Rovi warned that its 2024 EBITDA would be 10% to 15% lower than market consensus, primarily due to anticipated lower activity in its CDMO business during Q4, leading to a significant share price decline. (TradingView News)
The company reported a 20% decrease in net profit for 2024, attributed to an 8% decline in operating income, mainly due to reduced revenues from COVID-19 vaccine manufacturing, highlighting challenges in sustaining pandemic-related revenue streams. (CreditRiskMonitor)
Rovi's decision to retain its CDMO business, despite receiving non-binding offers, raises concerns about the company's ability to capitalize on potential strategic partnerships or divestitures that could unlock shareholder value. (Nasdaq)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.
Rovi Financial Performance
Revenues and expenses
Rovi Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Rovi stock?
Rovi (ROVI) has a market cap of €2.8B as of July 31, 2025.
What is the P/E ratio for Rovi stock?
The price to earnings (P/E) ratio for Rovi (ROVI) stock is 21.36 as of July 31, 2025.
Does Rovi stock pay dividends?
Yes, the Rovi (ROVI) stock pays dividends to shareholders. As of July 31, 2025, the dividend rate is €0.75743 and the yield is 1.37%. Rovi has a payout ratio of 42.68% on a trailing twelve-month basis.
When is the next Rovi dividend payment date?
The next Rovi (ROVI) dividend payment date is unconfirmed.
What is the beta indicator for Rovi?
Rovi (ROVI) has a beta rating of 0.45. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.